Does Wegovy or Ozempic Raise Heart Rate? (Palpitations Explained)

Wegovy and Ozempic labeling reports increases in average heart rate, but a new flutter or racing sensation still needs attention. A trial average cannot tell you whether your own symptoms reflect a medication effect, fluid loss, low glucose or a rhythm problem. Tell the prescriber about new palpitations, especially at rest.

The two brands contain semaglutide but have different doses and approved uses. Their labeling provides product-specific findings; do not assume every formulation produces the same effect. See Ozempic vs Wegovy for that distinction.

Yes — it's a real, labeled effect

In adult weight-management trials, Wegovy injection increased mean resting heart rate by 1–4 beats per minute compared with placebo. The label instructs regular monitoring, reporting palpitations or racing at rest, and discontinuation if a sustained increase in resting heart rate occurs¹. Contact the prescriber promptly about a sustained change; the warning does not require a particular “marked” jump before review.

Ozempic's separate placebo-controlled trials reported a mean increase of 2–3 bpm with the 0.5 mg and 1 mg doses, while placebo participants had a mean decrease of 0.3 bpm⁹. These are separate studies, not a direct comparison. Earlier class studies of other GLP-1 medicines do not provide an exact semaglutide-specific average^2,3. Individual changes can be larger than the average.

Why does it happen? The mechanism

Research on GLP-1 signaling explores autonomic and cardiac pathways as possible contributors to heart-rate changes. The exact mechanism in a person taking semaglutide is not established by the label, and proposed pathways cannot identify the cause of an individual’s palpitations.

The first is a shift in the autonomic balance that sets your heart rate — the tug-of-war between the sympathetic ("accelerator") and vagal/parasympathetic ("brake") nervous systems. Human studies of long-acting GLP-1 agonists have measured a tilt in that sympatho-vagal balance consistent with a faster resting rate⁴.

The second is a direct effect on the heart's pacemaker itself. In preclinical (animal) work, GLP-1-receptor activation raised heart rate even when sympathetic nerve input was blocked — pointing to a cardiac-autonomous action at the sinoatrial node, the heart's natural pacemaker, independent of the stress-hormone pathway⁵. This is preclinical evidence, not proof of the mechanism in a person taking semaglutide. It cannot exclude anxiety, a rhythm disorder or another cause of symptoms, and it does not establish that a faster pulse is harmless.

"Palpitations" — what people actually report, and what they mean

"Palpitations" is a catch-all word for feeling your heartbeat — a thump, a flutter, a skipped beat, a racing sensation, or simply an awareness of a faster pulse. On semaglutide, several distinct things can produce that feeling, and they aren't equally concerning:

• •A change in resting rate. This is reported in the labels, but the sensation alone cannot establish its cause or safety^1,9.
• •Fluid loss. Vomiting or diarrhea can cause dehydration. Tell the clinician about symptoms and urine changes rather than assuming extra fluid will resolve the racing. See semaglutide and dehydration.
• •Low glucose. Racing, shakiness or sweating can occur with hypoglycemia, particularly with insulin or a sulfonylurea. Follow your glucose action plan; low blood sugar on semaglutide covers that separate risk.
• •A rhythm problem or another condition. Assessment may be needed to distinguish these possibilities. There is no evidence here to classify most semaglutide palpitations as benign.

How this sits alongside the proven heart benefit

Here's the part that confuses people most: how can a drug that raises heart rate also protect the heart? Both are true, and they're not a contradiction.

In the landmark SELECT trial, semaglutide 2.4 mg (the Wegovy dose) cut major cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% in adults with established cardiovascular disease plus overweight or obesity, without diabetes⁶. On the diabetes side, the SUSTAIN-6 trial found a 26% reduction in those events in high-risk people with type 2 diabetes⁷, and the related GLP-1 agonist liraglutide cut cardiovascular events in the LEADER trial⁸ — all in drugs that also nudge heart rate up. We walk through the full cardiovascular case, and exactly which populations it applies to, in do Wegovy & Ozempic protect the heart? (the SELECT trial).

These trials show cardiovascular benefit in their studied populations while also recording safety findings. They do not establish that a new racing or irregular heartbeat in an individual is safe. Benefit at the group level does not replace assessment of symptoms.

When to report symptoms and when to get urgent help

Report new palpitations or a racing heartbeat at rest to the prescriber. The Wegovy label directs regular monitoring and discontinuation for a sustained resting-rate increase¹. Ask for instructions rather than waiting for an arbitrary number of extra beats.

Get emergency help for palpitations that do not go away or occur with chest pain, shortness of breath, feeling faint or fainting. If such symptoms have stopped, arrange urgent medical advice rather than assuming the episode was harmless¹⁰. Do not drive yourself while unwell.

If your clinician recommends tracking your resting pulse, bring readings with timing, symptoms, dose changes and other medicines. A pulse is not a blood-pressure measurement; our semaglutide and blood-pressure guide explains that separate question.

Our dosing and side-effects guide explains the broader schedule. It does not establish a titration change that treats every heart-rate symptom.

What to take from the numbers

Wegovy and Ozempic labels report small average heart-rate increases, with individual variation. Report racing at rest or sustained changes; seek emergency help for persistent palpitations or associated chest pain, breathlessness or fainting. Do not use a trial average or cardiovascular benefit to label your own symptoms benign.

For the broader evidence, see semaglutide: results and side effects.